miR-489 participates in sensitizing breast cancer cells to chemotherapy through ULK1 downregulation, as well as hampering autophagosome degradation by targeting the lysosomal protein transmembrane 4 beta (LAPTM4B) (Soni et al., 2018). Here, LAPTM4B is linked to breast cancer.